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Human monoclonal antibodiesHybridoma cell lines (2E8, 8G8 and 5G12) producing fully humanmonoclonal antibodies (hMAbs) speciﬁc for
the pre-membrane (prM) protein of West Nile virus (WNV) were prepared using a human fusion partner cell
line, MFP-2, and human peripheral blood lymphocytes from a blood donor diagnosed withWNV fever in 2004.
Using site-directed mutagenesis of a WNV-like particle (VLP) we identiﬁed 4 amino acid residues in the prM
protein unique to WNV and important in the binding of these hMAbs to the VLP. Residues V19 and L33 are
important epitopes for the binding of all three hMAbs. Mutations at residue, T20 and T24 affected the binding
of hMAbs, 8G8 and 5G12 only. These hMAbs did not signiﬁcantly protect AG129 interferon-deﬁcient mice or
Swiss Webster outbred mice from WNV infection.Inc.Published by Elsevier Inc.Introduction
West Nile virus (WNV) is an emerging global pathogen causing
WN fever and meningoencephalitis. Since its introduction into the
Western Hemisphere in 1999 it has spread throughout North and
Central America and the Caribbean and currently is the leading cause
of mosquito-borne human encephalitis in the region (Mackenzie
et al., 2004). WNV is a member of the virus family, Flaviviridae, genus,
Flavivirus. It is maintained in an enzootic cycle between mosquitoes
and birds with humans and other vertebrate animals as incidental
hosts (Mackenzie et al., 2004). Other medically important ﬂaviviruses
include Japanese encephalitis virus (JEV), tick-borne encephalitis
virus (TBEV), yellow fever virus, St. Louis encephalitis virus (SLEV)
and the four serotypes of dengue virus (DENV).
WNV has a single-stranded positive sense, 11 kb RNA genome that
encodes 3 structural proteins at its 5′-end. The envelope (E) protein is
the major virion glycoprotein responsible for viral cell membrane
attachment and fusion. The capsid (C) protein binds the genomic RNA
to form the nucleocapsid. The pre-membrane (prM) protein is a
chaperone protein that assists in the maturation of the E protein, and
occurs as a prM/E heterodimer. The pr peptide is the amino terminal
part of the prM protein that is cleaved from prM by the multibasicprotease, furin. The pr stays associated with the virion to protect the
fusion peptide of the E protein from premature fusion until reaching a
neutral pH environment. Once the virion reaches a neutral pH, the pr
peptide dissociates resulting in the formation of a fusion competent
particle (Yu et al., 2009).
Many technologies have been developed to produce humanized or
fully human monoclonal antibodies (hMAbs). These include phage
display for selection of hFAbs and humanization of murine MAbs
(mMAbs) (Tsurushita et al., 2005), direct re-engineering of mMAbs
(Thibodeaux and Roehrig, 2009), using transgenic mice that have had
themurine genes for antibody production replacedwith human genes
(Lonberg, 2008), and transformation of activated B cells with Epstein
Barr virus to immortalize B-cells (Traggiai et al., 2004).
For arthropod-borne viruses (arboviruses), Hunt et al. (2006)
humanized the highly neutralizing Venezuelan equine encephalitis
virus (VEEV)-reactive mMAb, 3B4C-4, using combinatorial antibody
libraries and phage-display technology. The humanized version of
3B4C-4 has been shown to be protective in mice when given
prophylactically (Hunt et al., 2006). Subsequently, hMAbs were
prepared against VEEV using phage display to produce VEEV-reactive
hFAbs, and their protective and therapeutic capacity is currently being
investigated (Hunt et al., 2010). The humanized anti-WNV antibody,
Hu-E16, was also developed using phage display technology. This
MAb binds to a highly conserved epitope on domain III of the WNV
envelope protein and has been shown to protect mice from lethal
virus challenge (Oliphant et al., 2005). The Hu-E16 MAb is in
Fig. 1. Protein speciﬁcity of hMAbs on WNV proteins. A Western blot of WNV proteins
was prepared as described in Materials and methods. Lane 1, Bio-Rad broad-range
protein standard (sizes are shown in kDa); Lane 2, mouse hyper-immune ascitic ﬂuid;
Lane 3, WNV human immune serum; Lane 4, WNV human immune serum from donor
of PBLs used to make hMAbs; Lane 5, hMAb 2E8; Lane 6, hMAb 8G8; Lane 7, hMAb
5G12; Lane 8, puriﬁed WNV total protein stain.
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(Beigel et al., 2010). By immortalizing the peripheral blood lympho-
cytes (PBLs) with Epstein Barr virus from a person recently infected
with dengue virus (DENV), Schieffelin et al. (2010) were able to show
that this technology is a viable option for the production of MAbs
against DENV (Schieffelin et al., 2010). Beltramello et al. (2010) have
recently published their work isolating anti-DENV hMAbs in the same
way (Beltramello et al., 2010). Direct humanization of the ﬂavivirus
group-reactive mMAb 6B6C-1 converted this mouse IgG MAb to
human IgM and IgG (Thibodeaux and Roehrig, 2009). These
humanized antibodies can be used as positive control antibodies for
all ﬂaviviruses in human antibody-speciﬁc diagnostic assays.
We have used a new technology to develop hMAbs that are
produced by fusing a human cell line, MFP-2, with human B cells
from PBLs. The MFP-2 cell line was developed by ﬁrst generating the
heteromyeloma (B6B11) by fusing a murine myeloma cell line with a
human myeloma cell line. B6B11 was then subsequently fused with
human lymph node lymphocytes to produce the trioma cell line,
MFP-2 (Kalantarov et al., 2002). The MFP-2 cell line was fused with
the PBLs from a person who had been infected with WNV in 2004,
and three hybridomas producing hMAbs reactive to WNV were
isolated and characterized.
To investigate the protein speciﬁcities of these hMAbs we used
virus-like particles (VLPs) as antigen in ELISA. These VLPs have been
used previously to identify binding sites of E protein-speciﬁc mMAbs
for DENV, WNV, and SLEV (Crill and Chang, 2004; Crill et al., 2007;
Trainor et al., 2007). For DENV, JEV, and SLEV the prM→M processing
does not occur, and only prM and E occur in VLPs (Hunt et al., 2001;
Purdy and Chang, 2005; Purdy et al., 2004). The prM→M cleavage of
the WNV VLPs is inefﬁcient, so the WNV VLP contains E, prM, and M
proteins (Davis et al., 2001). Interestingly, only TBEV-derived VLPs
contain only E and M protein (Schalich et al., 1996).
These hMAbs reacted only with WNV, and reacted with the WNV
prM protein. Using site-directed mutagenesis of the WNV VLP system
we identiﬁed amino acids (a.a.) important in hMAb binding. Residues
V19 and L33 of the prM protein were determined to be the important
sites for binding of all 3 hMAbs.Mutations at residues T20 and T24 had
some affect on binding of two hMAbs. When tested in mice for their
ability to inhibit lethal WNV infection, hMAbs, 8G8 and 5G12 slightly
increased the median survival time (MST) of WNV-infected AG129
and Swiss Webster (SW) mice, respectively; however, neither hMAb
fully protected animals from lethal infection.
Results
Production of hMAbs to WNV
We previously described the construction of a unique fusion
partner cell line, MFP-2, and its use for the immortalization of human
PBLs (Kalantarov et al., 2002). Three independent, fully hMAbs, 2E8,
8G8 and 5G12, were generated using this protocol with PBLs from a
donor diagnosed with WN fever in 2004. These hMAbs were found to
be IgG1 λ-chain isotype by ELISA.
Characterization of hMAbs
To determine the protein speciﬁcity of these hMAbs, reduced and
non-reduced puriﬁed WNV NY99 was separated on a 4–12% Bis/Tris
polyacrylamide gel and used as antigen in immunoblots. All three
hMAbs reacted speciﬁcally with non-reduced prM protein which is
approximately 20 kDa inmass (Fig. 1, Table 1). The three hMAbs failed
to react with reduced prM protein (data not shown) indicating that
the reactive prM epitopes were conformational in nature. The hMAbs
did not react with the M protein (approximately 6 kDa) suggesting
that they recognize the pr portion of the prM. Interestingly, serumfrom the donor of the PBLs used to make the hMAbs was also tested in
the immunoblot and only reacted with the E and C proteins of WNV.
A panel of 7 ﬂavivirus VLP antigens (DENV 1–4, JEV, WNV, and
SLEV) was used to test for virus cross-reactivity of the hMAbs (Davis
et al., 2001; Hunt et al., 2001; Purdy and Chang, 2005; Purdy et al.,
2004). The VLPs were derived from transformed COS-1 cells (Davis et
al., 2001). The VLPs were concentrated by ultracentrifugation (Purdy
et al., 2004), and the concentration of VLP bound to a well was
standardized by VLP-capture using the broadly ﬂavivirus-reactive
mMAb, 4G2. Flavivirus group-reactive human serum was used as a
positive control antibody. An OD of two times the background was
considered a positive result and endpoints are expressed in μ/ml of
hMAb. All three hMAbs reacted only with WNV antigen indicating
that these hMAbs are most likely WNV speciﬁc (Table 1). To assess
whether these hMAbs could neutralize virus hybridoma supernatants
were tested in a plaque reduction neutralization test (PRNT) with
WNV NY99. None of the hMAbs neutralized virus at a 90% plaque
reduction level (Table 1). The PRNT90 titer of the donor serum was
determined to be 1:80.prM hMAb binding site analysis
To identify the speciﬁc binding sites of these hMAbs we prepared
VLPs with changes in the prM a.a. sequence using site-directed
mutagenesis of the pVAXWN plasmid. Since these hMAbs were found
to be speciﬁc for WNV, we compared the a.a. sequence similarity of 10
ﬂaviviruses in the pr portion of the prM protein using GeneDoc
(version 2.6.002) software. Nine WNV-speciﬁc a.a. residues were
identiﬁed (Fig. 2). Corresponding residues were identiﬁed on the
crystal structure of the prM-E heterodimer of DENV2 virus at neutral
pH using Swiss Pdb Viewer (version 4.0.1) software to predict surface
accessible sites of the protein (Fig. 3). Five of the WNV speciﬁc pr a.a.s
were found to occur in surface accessible sites (V19, T20, T24, K31 and
L33), while the other 4 sites (T70, S72, R77 and K83) were predicted
to be internally located in the protein. We focused our mutagenesis
efforts on the 5 surface accessible sites, and produced 18 mutant
plasmids (Table 2). The mutant plasmids were transfected into COS-1
cells, and the resulting VLPs were used as antigens in ELISA as
Table 1
Serological and biological characteristics of hMAbs.
hMAba Isotype Immunoblotb PRNT (N90%)c Capture ELISAd
−ME +ME DEN1 DEN2 DEN3 DEN4 JE WN SLE
2E8 IgG1 prM O N6.7 N0.67 N0.67 N0.67 N0.67 N0.67 ≤0.004 N0.30
8G8 IgG1 prM O N6.0 N0.60 N0.60 N0.60 N0.60 N0.60 ≤0.020 N0.55
5G12 IgG1 prM O N5.5 N0.55 N0.55 N0.55 N0.55 N0.55 ≤0.028 N0.75
Anti-WN hse ntf E, C nt 1:80 nt nt nt nt nt nt nt
Bold indicates more than two-fold increase in reactivity of hMAb with antigen compared to negative control.
a Human monoclonal antibodies analyzed.
b Protein speciﬁcities: E, envelope protein, C, capsid protein, prM, premembrane protein; O, no reactivity detected.
c Plaque reduction neutralization activity of hMAb recorded as mg/ml, or anti-WNV human immune serum able to neutralize 90% of virus.
d Endpoint titers expressed in μg/ml of hMAb using VLP as antigen.
e Anti-WNV human immune sera—sera from donor of PBLs used to make hMAbs.
f Not tested.
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the wells was standardized by capture with a polyclonal anti-prM
and E WNV rabbit serum raised against WT WNV VLP. We used this
more broadly cross-reactive polyclonal rabbit antibody as capture
antibody in case the prM mutations altered the expression of the E
protein epitope reactive with 4G2. A human serum sample con-
taining anti-ﬂavivirus antibodies was used as detector antibody.
Concentrations of VLP producing an absorbance of 1.0 (450 nm)
were used in subsequent ELISAs to determine epitope speciﬁcity
(data not shown).
Results of the mapping are expressed as a fold-reduction in the
hMAb end-point titer of the mutant VLP compared to the WT WNV
VLP antigen. Since mutants were tested on individual transfectants
we compared the absolute endpoints and used fold differences to
compare mutant and WT VLP reactivity. A 4-fold or greater reduction
in the reactivity was considered signiﬁcant (Table 3). Generally, the
hMAbs were reactive with the mutant VLPs to some degree except
for mutations made at V19 and L33. When the V19 in the pr peptide
was mutated to N or T there was a loss of reactivity with all three
hMAbs. Similarly, when L33 was mutated to any of 4 a.a. substitu-
tions made (A, K, Q, or T) all reactivity was lost with the hMAbs. Four
mutations were made that did not result in a signiﬁcant loss of
reactivity with the hMAbs (V19R, T20G, T24L and T24R, data not
shown). When A was substituted for either T20 or T24 there was a
reduction in reactivity with hMAbs 8G8 and 5G12. Additionally,
when T20 was mutated to a Q there was a loss of reactivity only with
5G12. There was some loss of reactivity with hMAbs (V19A with
5G12 and T24A with 2E8) but since the reduction was less than four-
fold these were not considered signiﬁcant.
When VLPs were tested for secretion in an ELISA using rabbit
hyper-immune serum as capture antibody and human polyclonal
serum as detector antibody, four mutations (T20D, K31A, K31V, and
K31T) abrogated VLP secretion. Since these mutant VLPs could not be
tested by ELISA, we ﬁxed the mutant-transfected COS-1 cells and
tested the hMAbs' ability to bind to intracellular antigens by
immunoﬂuorescence. All of the mutant transfected cells bound wellFig. 2. Amino acid sequence homology in the pr peptide of ﬂaviviruses. The a.a. sequence hom
toWNV in the pr peptide. Nine amino acid residues (shown in black with the position highlig
and L33) and 4 interior residues (T70, S72, R77 and K83).with the anti-prM hMAbs, with no signiﬁcant increase or decrease in
reactivity(data not shown).Animal protection studies
We tested the ability of these hMAbs as a prophylactic treatment
for WNV infection in both Swiss Webster (SW) outbred mice and
interferon deﬁcient AG129 mice. Three groups (n=10) of AG129 or
SW mice were treated with 500 μg of hMAb 8G8, 500 μg of hMAb
5G12, or 500 μg of a hMAb to tetanus toxoid (hMAb TT) as a negative
control antibody (Table 4). AG129 and SW mice inoculated with PBS
(n=3 and n=6, respectively) served as an additional negative
control group. Since the hMAbs were non-neutralizing it was
unknown whether they would protect mice from a lethal WNV
infection, therefore we used a high dose of hMAb to test their
protective capacity. Twenty-four hours after inoculation with hMAb,
mice were challenged with 100 PFU of WNV NY99 a dose previously
determined to be 100% lethal for AG129 mice and 83% lethal for SW
mice (Calvert et al., 2006; Yamshchikov et al., 2004). Mice were
monitored for signs of morbidity, including weight loss, a change in
body temperature, and neurological signs of infection. While no
AG129 mice survived WNV challenge, MSTs of the mice treated with
hMAb 8G8 were signiﬁcantly longer than those treated with the
hMAb TT (P=0.0007). Relative to the control group treated with the
hMAb TT, treatment with 8G8 followed by WNV challenge increased
mouse MST by 1 day. The mouse group treated with 5G12 did not
have an increase in MST (4 days) followingWNV challenge compared
to those mice treated with hMAb TT (P=0.6; 4 days) (Table 4). When
SWmice were treated with 5G12, 3 out of 10 mice survived challenge
compared to 1 out of 10 mice treated with 8G8, and none survived
challenge when treated with hMAb TT. The MST for mice treated with
5G12 was 9 days, a signiﬁcant increase when compared to mice
treated with TT (P=0.007, 7.5 days). Mice treated with 8G8 had a
MST of 8.0 days which was not considered signiﬁcant when compared
to the MST of mice treated with TT (P=0.24).ologies of 10 ﬂaviviruses were compared in order to determine the a.a. residues unique
hted in gray) were identiﬁed including 5 surface accessible residues (V19, T20, T24, K31
Fig. 3. DEN2 prM-E heterodimer. The image (PDB ID: 3C6E) shows a top view towards
the viral surface of the DEN2 prM protein at neutral pH oriented near the fusion peptide
in domain II of the E glycoprotein. In the inset, the E protein structural and functional
domains I, II and III are shown in red, yellow and blue, with the fusion peptide in
domain II shown in cyan. The prM protein is shown in green, with the WNV epitopes
important in the hMAbs' binding shown in space-ﬁlling representations. V19 and L33
are highlighted in red. T20 and T24 are highlighted in orange. Disulﬁde bonds in the pr-
peptide are shown in magenta.
Table 3
Effect of hMAb binding to WN VLP antigen after amino acid substitutions in pr peptide.
pr a.a. substitutiona Fold change in hMAb titer with pr mutantsb
2E8 8G8 5G12
WT prM 1 1 1
V19A 2.5
V19N N256 N256 N256
V19T 9 24 64
T20A 4 4
T20Q 4.5
T24A 2.5 129 516
L33A 10.0 9.9 40.1
L33K N102 N102 N103
L33Q 412 128 206
L33T 13.6 25.6 103
a Amino acid substitution at speciﬁc residue in pr portion of the protein.
b Four-fold reduction or more (bold) in MAb end-point titer of mutant VLPs
compared to wild type VLP). Blank means two-fold or less reduction in titers. Actual
end-point titration on wild-type (WT) prM containing VLP with these MAbs were:
2E8=0.0161 μg/ml, 8G8=0.0256 μg/ml, and 5G12=0.0321 μg/ml.
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This is the ﬁrst report of the isolation and characterization of
fully hMAbs to WNV with PBLs from a person previously infected
with the virus fused to MFP-2 cell lines. Previously, MFP-2 cells
have been used to develop fully hMAbs to breast cancer associated
antigens (Kalantarov et al., 2002; Kirman et al., 2002; Rudchenko
et al., 2008).
While an abundance of information exists on the structure and
function of the E protein and its importance in ﬂavivirus immunity in
mice and humans, little is known about prM and its role in immunity.
This study is the ﬁrst report of the development and characterization
of hMAbs for the WNV prM protein, their use in analyzing the
antigenic structure of WNV prM, and its contribution to protective
immunity. These hMAbs were found to be WNV type-speciﬁc and the
epitopes they recognize mapped to the most variable region of the
prM protein. Not surprisingly, evaluation of the high-resolution
crystal structure of the DENV2 prM-E heterodimer at neutral pH,
revealed that the region for binding of these pr-speciﬁc hMAbs (V19Table 2
Nucleotide sequences of primers used for mutagenesis.
Primer Mutagenic primer sequence (5′–3′)a
V19A GGTAAATGCTACTGACGCCACAGATGTCATCACGA
V19N GGTAAATGCTACTGACAACACAGATGTCATCACGA
V19R GGTAAATGCTACTGACAGGACAGATGTCATCACGA
V19T GGTAAATGCTACTGACACCACAGATGTCATCACGA
T20A GTAAATGCTACTGACGTCGCAGATGTCATCACGATTC
T20D GTAAATGCTACTGACGTCGACGATGTCATCACGATTC
T20G GTAAATGCTACTGACGTCGGAGATGTCATCACGATTC
T20Q GTAAATGCTACTGACGTCCCAGATGTCATCACGATTC
T24A CGTCACAGATGTCATCGCGATTCCAACAGCTGC
T24L CGTCACAGATGTCATCCTGATTCCAACAGCTGC
T24R CGTCACAGATGTCATCAGGATTCCAACAGCTGC
K31A GATTCCAACAGCTGCTGGAGCGAACCTATGCATTGTCAGA
K31V GATTCCAACAGCTGCTGGAGTGAACCTATGCATTGTCAGA
K31T GATTCCAACAGCTGCTGGAACGAACCTATGCATTGTCAGA
L33A AACAGCTGCTGGAAAGAACGCATGCATTGTCAGAGCAATG
L33K AACAGCTGCTGGAAAGAACAAATGCATTGTCAGAGCAATG
L33Q AACAGCTGCTGGAAAGAACCAATGCATTGTCAGAGCAATG
L33T AACAGCTGCTGGAAAGAACACATGCATTGTCAGAGCAATG
a The mismatched nucleotides causing the desired substitutions are shown in bold.and L33, highlighted in red in Fig. 3) are localized at the top of the prM
protein (Li et al., 2008). The other residues that affected binding of
hMAbs, T20 and T24 (highlighted in orange in Fig. 3) are in close
proximity to V19 and L33. While these a.a. were important in the
binding of hMAbs 8G8 and 5G12, their inﬂuence may be due to
mutations made in this region that change the epitope only slightly
(e.g., T20A or T24A changes). The T20Q mutation may sterically
obstruct the ability of the hMAbs to bind to the key epitope at V19.
It is interesting that all three of these hMAbs were found to be
speciﬁc for the prM protein of WNV, since the donor serum was most
reactive with the E and C proteins. While much is known about the
structure and composition of ﬂaviviruses grown in cell culture,
nothing is known about the structure and composition of the virus
as it replicates in either vertebrate or mosquito hosts. We know that
the prM→M cleavage is dependent on both the prM→M cleavage
motif and the cells in which the virus grows (Fischl et al., 2008;
Keelapang et al., 2004; Randolph et al., 1990). It is conceivable that
ﬂaviviruses circulating in the vertebrate host might contain a
signiﬁcant amount of prM-containing immature particles. If this is
the case, a robust anti-prM antibody response might be expected.
While little is known about the protective capacity of antibodies to
prM, some studies have shown that prM is able to induce protective
antibody responses in mice. Kaufman et al. (1989) isolated 5 anti-prM
mMAbs to DENV3 and DENV4. These were shown to passively protect
mice against homologous as well as heterologous DENV challenge.Nucleotide mutation Amino acid substitution
GTC-GCC Val-Ala
GTC-AAC Val-Asn
GTC-AGG Val-Arg
GTC-ACC Val-Thr
ACA-GCA Thr-Ala
ACA-GAC Thr-Asp
ACA-GGA Thr-Gly
ACA-CCA Thr-Gln
ACG-GCG Thr-Ala
ACG-CTG Thr-Leu
ACG-AGG Thr-Arg
AAG-GCG Lys-Ala
AAG-GTG Lys-Val
AAG-ACG Lys-Thr
CTA-GCA Leu-Ala
CTA-AAA Leu-Lys
CTA-CAA Leu-Gln
CTA-ACA Leu-Thr
Table 4
Median survival times of AG129 mice treated with hMAbs and challenged with WNV
24 h later.
Groupa AG129 Survivors/total AG129 MST SW Survivors/total SW MST
8G8 0/10 5b 1/10 8
5G12 0/10 4 3/10 9
TT 0/10 4 0/10 7.5
PBS 0/3 3 1/6 7.5
a AG129 or Swiss Webster (SW) mice treated i.p. with 500 μg of hMAb or PBS.
b Median survival time in days.
34 A.E. Calvert et al. / Virology 410 (2011) 30–37Two out of ﬁve of the MAbs were found to have some neutralizing
activity while four out of ﬁve were also able to ﬁx complement
(Kaufman et al., 1989). By constructing recombinant vaccinia viruses
expressing prM, M or pr proteins of DENV4 virus, Bray and Lai (1991)
found that mice immunized with the recombinant prM or M were
protected against homologous virus challenge. However, vaccinating
with the recombinant virus expressing pr alone was not protective
(Bray and Lai, 1991). Synthetic peptides of the DENV2 prM protein
were found to elicit neutralizing antibody that was protective against
virus challenge. A synthetic peptide of the DENV2 prM protein
containing residues 1–33 (B19-6) was found to elicit neutralizing
antibody in mice that allowed for a protective response against
DENV2 challenge (Vazquez et al., 2002). It is interesting that this
peptide contained all of the a.a that we have deﬁned as critical to the
binding of our pr-speciﬁc hMAbs.
We found these hMAbs to beminimally protective in outbredmice
as well as interferon deﬁcient mice. These anti-prM hMAbs also did
not neutralize WNV infectivity in vitro. The non-neutralizing capacity
of our hMAbs may be due to a reduced number of epitopes available
on the virion to which the antibody can bind after prM/M cleavage.
The cleavage of the prM protein by furin in the secretory pathway
results in the M protein being present in the mature viral envelope.
Once the virion has reached a neutral pH the pr peptide dissociates,
resulting in a fusion-competent particle (Yu et al., 2009). As stated
previously, since this cleavage by furin can be inefﬁcient not all virions
released from cells may contain solely M, and in fact, there might be a
mixed population of virions containing only M, only prM or a mixture
of prM and M on the virion surface (Cherrier et al., 2009).
Consequently, the availability of prM to pr-reactive antibody likely
varies from virus to virus, and also from cell type to cell type in which
the virus grows.
It has been shown that complete maturation of ﬂavivirions results
in a reduction of neutralization with E protein-speciﬁc antibodies
reactive with epitopes that may be more accessible in immature
forms of the virus (Nelson et al., 2008). It is also necessary for
antibodies that recognize epitopes that are not surface exposed to
have more sites bound in order to neutralize the virus (Pierson et al.,
2007). It is possible that the virus used to challenge mice contained
more M than prM, and therefore, there was a lack of surface-exposed
epitopes for antibodies to bind resulting in an inability of the
antibodies to neutralize virus effectively and protect mice from a
lethal virus infection.
Four mutations made in the WN VLP (T20D, K31A, K31V, K31T)
resulted in failure of transfected cells to release particles. Although
VLPs were not secreted with these mutations, prM was identiﬁed in
the virus-infected cells. These and other mutations made in the
pVAXWN plasmid were near the N-terminal of the protein. It seems
unlikely that these mutations would have an effect on cleavage of
prM→M, and their inﬂuence on antigen secretion must be due to
another mechanism. Little has been reported on the requirements in
the prM protein for effective viral maturation and secretion. Tan et al.
(2009) found that the highly conserved Y78 residue in the
ectodomain of the prM was essential for virus assembly and secretion
from cells in vitro, while mutations made at V76, R77 or G79 had noeffect (Tan et al., 2009). H99 was also found to be critical for the
formation of stable prM-E heterodimers (Lin and Wu, 2005). In
analyzing the structure of the prM-E heterodimer, Li et al. (2008)
found three areas in the pr (R6; E46, D47; and D63, D65) that may be
involved in electrostatic bonds with the E protein, therefore
mutations in this region may have an effect on prM-E formation and
particle secretion (Li et al., 2008). All of the residues reported to have
an effect on viral particle maturation and secretion are in the interior
regions of the protein. All mutations we introduced at residue K31
resulted in lack ofWNV VLP secretion. This residue is on the surface of
the pr peptide and does not appear to interact with the E protein in
the heterodimer, or on the neighboring E protein in particle assembly,
but in fact, its placement is at the top of prM, which sits on top of the E
protein in the immature particle. More investigation into the
mutations at K31 alongwith themutation T20D need to be completed,
and experiments are ongoing to determine if K31 is a critical element
for WNV particle maturation and secretion.
Recent studies have explored the possibility of prM antibodies
facilitating the infection of DENV in vitro. Antibodies to the prM
protein can enhance DENV infection with non-Fc receptor bearing
cells, suggesting a mechanism different from that of anti-E
antibodies (Huang et al., 2008; Huang et al., 2006). Speciﬁcally,
human anti-prM antibodies to the M3 epitope (a.a. 52–67) cross-
reacted with epithelial, kidney, endothelial cells and T lymphocytes.
They were also found to cross-react with heat shock protein 60
(HP60) on the surface of BHK and A549 cells. This interaction may
cause apoptosis in endothelial cells or may indirectly cause
complement mediated cytotoxicity or antibody dependent cellular
cytotoxicity (Huang et al., 2008). It is likely that anti-prM antibodies
to DENV assist immature particles in cell entry where they are able
to undergo the conformational change and cleavage of the prM
protein by furin in the acidic endosomal environment making an
otherwise non-infectious virus particle infectious. Therefore, pre-
existing heterotypic anti-prM antibodies may assist in increasing the
viral load in secondary infections (Dejnirattisai et al., 2010;
Rodenhuis-Zybert et al., 2010).
The hMAbs described here offer a new tool in understanding the
human immune response to WNV. While most studies of prM have
been in the context of creating an immunogenic virus particle with
the E protein for vaccinations, it should not be assumed that the anti-
prM antibody response in humans is not important. Although our
results indicate that these anti-prM antibodies did not offer a
signiﬁcant source of protection in mice, the inclusion of anti-prM
antibodies in the human antibody repertoire may be more important
than previously considered. Further study into the immunogenic
capacity of prM in humans or humanized animal models is necessary
in order to fully understand the importance of prM in aWNV infection.
Materials and methods
Cells and viruses
C6/36 cells and COS-1 cells were cultured as described previously
(Davis et al., 2001; Huang et al., 2000). WNV strain, NY99 35262,
originally isolated from a Chilean ﬂamingo at the Bronx Zoo (NY, USA)
in 1999, was obtained from the Arbovirus Diseases Branch, Diagnostic
and Reference Activity, CDC. The virus was passaged once in suckling
mouse brain and twice in C6/36 cells. Stock virus was grown in C6/36
cells to a titer of 1.5×109 PFU/ml.
Production of hMAbs to WNV
Hybridoma cell lines, secreting 2E8, 8G8 and 5G12 fully hMAbs,
were produced as a result of PEG-fusion between the MFP-2 fusion
partner cell line and human PBLs from a donor diagnosed with WN
fever (Kalantarov et al., 2002). All three cell lines were maintained in
35A.E. Calvert et al. / Virology 410 (2011) 30–37RPMI 1640 media (Invitrogen) supplemented with 10% FBS, L-
glutamine, non-essential amino acids, Na pyruvate, and vitamins.
Positive hybridomas were selected in ELISA, using mMAb, D1-4G2-4-
15, as a capturing antibody (ATCC cat# HB-112). Plates were coated
overnight with 4G2, then washed and blocked with 1% BSA in PBS.
Plates were then incubated with WNV-VLP (1:20) and COS-1 (1:20)
negative control (Hennessy Research, cat# P120-1) for 2 h, washed,
and incubated with hybridoma supernatants, as well as positive and
negative human sera for 1 h. Goat–anti-human IgG-HRP (mouse
adsorbed, Invitrogen cat# H10507)was used as the detector antibody.
Hybridomas were also adapted for growth in serum-free media (HyQ-
CCM1, HyClone, cat# SH30043.03). Hollow ﬁber cartridges 4300-
C2011 (Fiber Cell Systems) were used for large-scale production of all
three hMAbs.
Puriﬁcation of virus
WNV NY99 was grown in C6/36 cells and puriﬁed on a glycerol
tartrate gradient as described by Obijeski et al. (1976). The puriﬁed
stock was used in the immunoblot (Obijeski et al., 1976).
Puriﬁcation of hMAbs
For animal studies, hMAbs 2E8, 8G8 and 5G12 were puriﬁed from
highly concentrated culture media using protein A/G agarose (Pierce,
cat# 20423) according to the manufacturer's instructions. HMAbs
were further dialyzed against PBS and the concentration was
measured in ELISA using puriﬁed human IgG (GenScript, cat#
A01006) as the calibrator.
Immunoblotting
WNV proteins from puriﬁed virus were separated by SDS-PAGE on
a reduced or non-reduced 4–12% Bis/Tris polyacrylamide gel
(Invitrogen). All procedures were performed at room temperature.
Proteins were blotted electrophoretically from the gels onto nitro-
cellulose membranes and washed for 15 min in PBS/0.1% Tween wash
buffer. Non-speciﬁc binding sites were blocked with 1% BSA/PBS for
1 h while rocking. Undiluted hybridoma supernatants were incubated
with the membrane for 1 h with gentle rocking. Membranes were
washed again in PBS/0.1% Tween wash buffer three times for 5 min
each. Goat anti-human antibody conjugated to horseradish peroxi-
dase (Invitrogen) was diluted 1:500 and incubated on the membrane
for 1 h with gentle rocking. Membranes were washed and Novex HRP
chromogenic (TMB) substrate (Invitrogen) was added to the
membrane until a color change appeared. The reaction was stopped
by the addition of water.
Plaque-reduction neutralization test (PRNT)
Human serum was heat-inactivated at 56 °C for 30 min. One
hundred plaque forming units (PFU) of WNV NY99 were incubated
with equal amounts of serial two-fold dilutions of hybridoma
supernatant or human serum for 1 h at 37 °C. Six-well plates of Vero
cells were then inoculated with the virus–antibody mixtures and
incubated at 37 °C with 5% CO2 for 1 h after which cells were overlaid
with 3 ml of medium containing 1% SeaKem LE agarose (FMC
BioProducts) in nutrient medium (0.165% lactalbumin hydrolysate,
0.033% yeast extract [Difco], Earle's balanced salt solution and 2% FBS).
Following incubation at 37 °C for 2 days a second overlay containing
additional 80 μg of neutral red vital stain (GIBCO-BRL) per ml was
added. Plaques were counted on day 3 and endpoint titers were
expressed as the concentration of antibody (mg/ml) that yielded 90%
reduction in the number of plaques (PRNT90).Site-directed mutagenesis
Site-speciﬁc mutations were introduced into the prM gene using
the QuikChange Site-Directed Mutagenesis kit (Stratagene), with
pVAXWN plasmid previously described as a DNA template (Davis
et al., 2001). Mutagenic primer sequences used for all constructs are
listed in Table 2. After transformation with mutagenic PCR products,
colonies were grown in Luria–Bertani broth (5 ml); plasmid was
puriﬁed and sequenced to determine the correct mutation was
present, and then the structural genes and regulatory elements of all
puriﬁed plasmids were sequenced. Automated DNA sequencing was
performed with a 3130X Genetic Analyzer (Applied Biosystems) and
sequences were analyzed with Lasergene software (DNAStar).
Molecular modeling of the mutations was constructed using Pymol
software (v0.99) and the PDB image (3C6E) (Li et al., 2008).
Transient expression of WN VLP in COS-1 cells by electroporation
COS-1 cells were electroporated with the pVAXWN plasmid as
previously described (Davis et al., 2001). Electroporated cells were
recovered in 6 ml of DMEM supplemented with 10% fetal calf serum
(FCS). Cells were seeded into 25-cm2 culture ﬂasks for VLP expression,
and incubated at 37 °C with 5% CO2. Six hours after electroporation,
the growth medium in ﬂasks was replaced with DMEM containing 2%
FCS. Tissue culture medium and cells were harvested 5 days after
electroporation for antigen characterization by ELISA and
immunoﬂuorescence.
ELISAs
All ELISAs were performed in 96-well plates (Maxisorp plates,
Nunc). Starting concentrations of hMAbs from serum-free hybridoma
supernatant in ELISAs were as follows: 2E8, 6.7 μg/ml, 8G8, 6.0 μg/ml,
5G12, 5.5 μg/ml. Starting concentrations of hMAbs to test for cross-
reactivity with WN and SLE VLP were as follows: 2E8, 3.0 μg/ml, 8G8,
5.5 μg/ml, 5G12, 7.5 μg/ml. All ﬂaviviral VLP antigens in ELISAs to
determine cross-reactivity were obtained from the Reference Collec-
tion of the Diagnostic Lab, DVBID, CDC. Plates were coated with a
capture antibody, ﬂavivirus group-reactive mMAb 4G2 ascitic ﬂuid
diluted 1:1000 in carbonate/bicarbonate buffer (50 mM sodium
carbonate, 50 mM sodium bicarbonate, pH 9.6) and incubated
overnight at 4 °C. Plates were washed ﬁve times with PBS/0.1%
Tween wash buffer with an automatic plate washer. Non-speciﬁc
binding sites were blocked with Pierce Starting Block (PBS) blocking
buffer (100 μl/well). Blocking buffer was immediately removed before
ﬂavivirus antigen diluted in PBS was added to the wells (50 μl/well).
VLP antigen was incubated on the plates for 2 h at 37 °C, after which
the plates were washed as previously described. Hybridoma super-
natant was added in 3-fold dilutions (50 μl/well) and incubated for
1 h at 37 °C. Plates were washed ﬁve times before the addition of goat
anti-human antibody conjugated to horseradish peroxidase (50 μl/
well), diluted 1:3000 in 5% skim milk/PBS. After an incubation period
of 1 h at 37 °C, plates were washed again 10 times. Enhanced K-blue
TMB substrate (Neogen) was added to each well of the plate (100 μl/
well) and incubated in the dark at room temperature for 10 min. The
reaction was stopped with the addition of 1 N H2SO4 (50 μl/well), and
the plates were read at 450 nm.
For the standardization of mutant WN VLPs the protocol remained
the same with some exceptions. The capture antibody, 4G2, was
replaced with rabbit hyperimmune sera to WN prM and E proteins
diluted 1:1000. The antigen produced from transfections of COS cells
with the mutated pVAXWN plasmid were diluted two-fold in PBS.
Human sera positive for reactivity with all ﬂaviviruses was obtained
from the Reference Collection of the Diagnostic Laboratory, ADB,
DVBID, CDC, and used as the primary antibody at a dilution of 1:1000
in PBS. To test the reactivity of the mutant VLPs with the hMAbs, VLPs
36 A.E. Calvert et al. / Virology 410 (2011) 30–37were diluted appropriately to obtain a standardized amount of
antigen for all preparations. Hybridoma supernatant was used as
the primary antibody and added to the wells in four-fold dilutions
(50 μl/well), and the ELISA was carried out as described above.
Immunoﬂuorescence
In order to determine the reactivity of hMAbs with mutant VLP
plasmid that was unable to secrete particles, COS-1 cells were
harvested 5 days after transfection and ﬁxed to 12-well glass slides.
Cells were ﬁxed in 70% acetone in PBS. Hybridoma supernatant was
added in doubling dilutions (20 μl/well) to the wells of the slide and
incubated at 37 °C for 30 min. Slides were washed three times in PBS
and allowed to dry before goat anti-human conjugated to FITC
(Invitrogen) diluted 1:200 in PBS was added (20 μl/well) and
incubated at 37 °C for 30 min. Slides werewashed, dried andmounted
with Dabco mounting medium and examined on a Zeiss epiﬂuores-
cence microscope.
Mouse experiments
AG129 mice deﬁcient in IFN-α/β and -γ receptors (van den Broek
et al., 1995) and SWmice were bred in-house. The mice were handled
as speciﬁed by institutional guidelines for care and use in accordance
with the Institutional Animal Care and Use Committee recommenda-
tions. HMAbs, 8G8 and 5G12, were evaluated for their ability to inhibit
WNV infection in 5–8 week old AG129 mice, and 3–4 week old SW
mice. For each breed two groups of mice (n=10) were inoculated
intraperitoneally (i.p.) with 500 μg of hMAbs 8G8 or 5G12. One group
of mice (n=10) was inoculated i.p. with a hMAb of the same isotype
(IgG1) to tetanus toxoid (TT) as a control (hMAb TT). Another group
of mice (n=3, AG129 mice and n=6, SW mice) was inoculated i.p.
with 100 μl of PBS. Challenge was performed by i.p. inoculation with
100 PFU of WNV NY99 diluted in medium 24 h after the hMAb
inoculation (Calvert et al., 2006; Yamshchikov et al., 2004). Chal-
lenged mice were monitored for an increase followed by a decrease in
normal temperature measured by implantable temperature trans-
ponders (BMDS), weight loss and other signs of morbidity (hunched
posture, neurological signs). Mice that showed signs of morbidity
were euthanized immediately.
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